ECO ANIMAL HEALTH GROUP PLC

Report Publication Announcement • Nov 20, 2025

National Storage Mechanism | Additional information

RNS Number : 2684I

Eco Animal Health Group PLC

20 November 2025

20 November 2025

ECO Animal Health Group plc

("ECO" or the "Company")

Notice of Results

Analyst Briefing and Investor Presentation

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, will announce its unaudited interim results for the six months ended 30 June 2025 on 1 December 2025.

David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person analyst briefing at 09:00 GMT on 1 December 2025. There will be a dial-in option for those unable to attend in person. For further information about the analyst presentation, please contact [email protected].

In addition, David Hallas and Christopher Wilks will conduct a live online presentation and Q&A at 14:00 GMT on 2 December 2025.  This event is open to all existing and potential shareholders and registration is free. To register for the event, please click here.

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORMZMMMFLVGKZZ